|
Post by boca1girl on Oct 9, 2017 10:14:54 GMT -5
I spoke to a doctor friend on Saturday who had prescribed Afrezza to two patients over a year ago. She works at a federally funded clinic and the patients no longer go there. She was under the impression that Afrezza was off the market when SNY discontinued it and has not prescribed it since. When I told her MNKD was selling it and they just received fda approval of the enhanced label, she was surprised. What makes matters worse is that she is now pre-diabetic and sees nothing wrong with taking Metformin.
Education of the doctor population is EXTREMEMLY important if Afrezza is to exceed!
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Oct 9, 2017 10:20:25 GMT -5
Just because they are doctors doesn't imply intelligence. Most have good memorization abilities, but little deep thinking skills.
|
|
|
Post by od on Oct 9, 2017 10:23:03 GMT -5
Wow Kastanes, that is a sweeping statement. I feel the same about many investors.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Oct 9, 2017 10:30:09 GMT -5
Wow Kastanes, that is a sweeping statement. I feel the same about many investors. A doctor spends at least eight years in school and they don't understand the long-term consequences of elevated glucose levels?
|
|
|
Post by sweedee79 on Oct 9, 2017 11:06:45 GMT -5
Metformin is the standard of care. It’s what docs hav been taught to do, it’s what they know. Until they know something else they will continue prescribing Metformin.
|
|
|
Post by brotherm1 on Oct 9, 2017 12:07:45 GMT -5
I think generally in any profession, employees and proprieotrs over time tend to get set in their ways and advancements and changes in technology are not so easily kept up with. This rings especially true of the older well set employees/proprietors who are able to retire at any given time.
|
|
|
Post by kc on Oct 9, 2017 12:19:31 GMT -5
Metformin is the standard of care. It’s what docs hav been taught to do, it’s what they know. Until they know something else they will continue prescribing Metformin. They prescribe Metformin as you can get it for .25 per pill. Cheap and easy to prescribe for all medical plans. It does not matter that the outcome is not what a person wants. Its the outcome of the insurance community that matters.
|
|
|
Post by boca1girl on Oct 9, 2017 12:29:36 GMT -5
I spoke to a doctor friend on Saturday who had prescribed Afrezza to two patients over a year ago. She works at a federally funded clinic and the patients no longer go there. She was under the impression that Afrezza was off the market when SNY discontinued it and has not prescribed it since. When I told her MNKD was selling it and they just received fda approval of the enhanced label, she was surprised. What makes matters worse is that she is now pre-diabetic and sees nothing wrong with taking Metformin. Education of the doctor population is EXTREMEMLY important if Afrezza is to exceed! Some additional comments: This doctor friend is now 60 and WAS willing to try Afrezza for her patients two years ago. She was informed that the product was being discontinued, as SNY was not marketing it any longer, therefore she didn’t prescribe again. This doctor has a very large patient load at her clinic so I don’t blame her after being told the product was no longer available from SNY. Education/awareness is EXTREMELY important along with better insurance coverage.
|
|
|
Post by sportsrancho on Oct 9, 2017 12:38:33 GMT -5
Is she willing to call MNKD and have some reps come out?
|
|
|
Post by boca1girl on Oct 9, 2017 13:41:16 GMT -5
Is she willing to call MNKD and have some reps come out? Don’t know, I didn’t think to ask. I will ask her.
|
|
|
Post by babaoriley on Oct 9, 2017 16:07:39 GMT -5
Is she willing to call MNKD and have some reps come out? How about some MNKD reps call Doc and boca can alert Doc to expect same.
|
|
|
Post by slapshot on Oct 9, 2017 20:58:18 GMT -5
Just because they are doctors doesn't imply intelligence. Most have good memorization abilities, but little deep thinking skills. In Kastane's defense... I'm not real good with statistics, but remember reading that something like 50% of all doctors graduated in the lower half of their class. Seems like a lot, but I can believe it. Also on a side note, I play a lot of golf and have heard that some ungodly high number, upwards of 90%, of all puts hit short don't go in the hole. Not sure about that one, but that's what I've heard.
|
|
|
Post by boca1girl on Oct 9, 2017 21:50:54 GMT -5
Is she willing to call MNKD and have some reps come out? Yes. She would prefer a MNKD rep to contact her via LinkedIn to set something up. I’ll try to figure out how to send you a private message with her contact info.
|
|
|
Post by slugworth008 on Oct 9, 2017 22:00:52 GMT -5
I spoke to a doctor friend on Saturday who had prescribed Afrezza to two patients over a year ago. She works at a federally funded clinic and the patients no longer go there. She was under the impression that Afrezza was off the market when SNY discontinued it and has not prescribed it since. When I told her MNKD was selling it and they just received fda approval of the enhanced label, she was surprised. What makes matters worse is that she is now pre-diabetic and sees nothing wrong with taking Metformin. Education of the doctor population is EXTREMEMLY important if Afrezza is to exceed! Wow - captain obvious. Boca girl I take ALL of your posts with a small grain of salt. Your Afrezza glass is always half-empty. IMO - How about some tasty KERX stock?
|
|
|
Post by majorwood on Oct 9, 2017 22:32:08 GMT -5
My wife is both a Dr and MNKD investor. (Thanks in part to me educating her on this topic since 2014). She has watched along with all of us as bashers have bashed, as BP locked us in back room with no lights, food & water, witnessed the passing of our Mann, watched the wonderful and passionate CFO get outside his element and steer us towards brighter days, and finally we've all watched as energetic & brilliant Mike C has resurrected Al's dream with passion and focus getting this snowball rolling down the multi billion dollar mtn called Diabetes Care. We are on our way folks.
I want to thank my wife for never wavering and telling me, even when the stock price was $.69, that someday Afrezza and Technosphere would be great success. She's a keeper.
I'd like to raise a toast to all those that keep Al's vision alive. Nate Pile included.
Cheers
|
|